STOCK TITAN

Qualigen Therapeutics Inc Stock Price, News & Analysis

QLGN Nasdaq

Welcome to our dedicated page for Qualigen Therapeutics news (Ticker: QLGN), a resource for investors and traders seeking the latest updates and insights on Qualigen Therapeutics stock.

Qualigen Therapeutics Inc (QLGN) is an early clinical-stage biopharmaceutical company advancing novel cancer treatments through its investigational G-quadruplex-targeting therapies. This hub provides timely updates on corporate developments, clinical research milestones, and regulatory progress for investors and researchers.

Access press releases covering QN-302 clinical trials, preclinical program updates, financial disclosures, and strategic partnerships. Our curated news collection helps stakeholders track the company’s progress in developing precision oncology treatments while maintaining compliance with financial reporting standards.

Key updates include therapeutic pipeline advancements, peer-reviewed research publications, and material business events. All content is verified through primary sources to ensure accuracy and relevance for investment analysis and scientific evaluation.

Bookmark this page for consolidated access to Qualigen Therapeutics’ latest developments in cancer drug discovery and corporate announcements. Check regularly for authoritative updates on their innovative approach to targeting transcription mechanisms in malignant cells.

Rhea-AI Summary

Qualigen Therapeutics, Inc. (Nasdaq: QLGN) has filed a provisional patent application in partnership with the University of Louisville for a method to inhibit coronavirus infections using the antiviral candidate AS1411. This application aims to protect against SARS-CoV-2 via delivery mechanisms such as inhalers, nose sprays, or eye drops. The company plans to initiate IND-enabling studies and file for IND with the FDA in late 2020, with a goal to begin Phase 1/2 clinical trials in COVID-19 patients in early 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.99%
Tags
none
-
Rhea-AI Summary

Qualigen Therapeutics (Nasdaq: QLGN) has contracted with IRISYS LLC to manufacture its lead drug candidate AS1411, aimed at treating viral diseases, including COVID-19. Preclinical studies from the University of Louisville indicate AS1411’s potential to protect cells from the novel coronavirus. Qualigen plans to file an IND application with the FDA in Q4 2020 and initiate Phase 1/2 clinical studies early next year. The drug has shown safety in prior trials involving over 100 cancer patients. This step is crucial for advancing AS1411’s development as an antiviral therapeutic.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.43%
Tags
none
-
Rhea-AI Summary

Qualigen Therapeutics (Nasdaq: QLGN) has appointed Amy Broidrick to its Board of Directors, bringing over 25 years of pharmaceutical experience, including roles in the launches of VYTORIN™ and Celebrex™. Broidrick's background in corporate development and marketing is expected to support Qualigen’s therapeutic development initiatives, particularly drugs targeting cancer and COVID-19. The company focuses on innovative therapeutics and diagnostic systems, with its FastPack System currently in operation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.89%
Tags
management
Rhea-AI Summary

Qualigen Therapeutics, Inc. (NASDAQ: QLGN) has announced the issuance of patent No. 10,744,257 for its Selective Target Antigen Removal System (STARS™) technology, aimed at removing viral and tumor-produced compounds from blood. With this patent, Qualigen's intellectual property portfolio expands to 26 issued patents. The STARS technology, still in early development stages, shows promising in vitro results and is intended for applications in cancer and infectious diseases. Qualigen aims to leverage its existing diagnostic systems to further advance STARS.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.34%
Tags
none
-
Rhea-AI Summary

Qualigen Therapeutics reported its fiscal Q1 2021 results, showing total revenues of $0.9 million, down from $1.5 million in Q1 2020, largely attributed to the COVID-19 pandemic's impact on diagnostic test volumes. The company raised $18 million through equity financing, with cash reserves now at $16 million, adequate to fund operations into 2022. Significant developments include exclusive licensing agreements with the University of Louisville for cancer drug candidates and COVID-19 treatment. However, net loss surged to $18.6 million, inclusive of a $16.2 million non-cash charge for warrant liabilities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.73%
Tags
-
Rhea-AI Summary

Qualigen Therapeutics (NASDAQ: QLGN) will host a business update conference call on August 18, 2020, at 4:30 p.m. Eastern time. The call will cover the company's business strategy, drug development program, and fiscal first quarter 2021 financials. Participants can pre-register for immediate access. A replay will be available after the call and until August 25, 2020. Qualigen develops therapeutics for cancer and infectious diseases using FDA-approved diagnostics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.7%
Tags
conferences
Rhea-AI Summary

Qualigen Therapeutics announced the closing of a registered direct offering on Aug. 4, 2020, raising $10 million through the sale of 1,717,106 shares of common stock and 1,287,829 warrants. The offering was priced at $5.82375 per share and includes warrants with an exercise price of $6.00, valid for two years. A.G.P./Alliance Global Partners acted as placement agent. Qualigen focuses on developing therapeutics for cancer and infectious diseases, with its only commercial product currently being the FastPack diagnostic system.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.72%
Tags
-
Rhea-AI Summary

Qualigen Therapeutics, Inc. (NASDAQ: QLGN) announced a definitive agreement with an institutional investor for a $10 million registered direct offering. This includes the sale of 1,717,106 Common Shares and 1,287,829 Common Warrants at a combined price of $5.82375, effective on August 4, 2020. The Common Warrants have an exercise price of $6.00 and a two-year term. A.G.P./Alliance Global Partners is the sole placement agent for this offering, which is conducted under an effective shelf registration statement with the SEC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.2%
Tags
-
Rhea-AI Summary

Qualigen Therapeutics (NASDAQ: QLGN) has commenced commercial shipments of its FastPack SARS-CoV-2 IgG diagnostic test, intended for qualitative detection of COVID-19 antibodies. Submitted for Emergency Use Authorization (EUA) from the FDA, the FastPack tests can deliver results in approximately 10 minutes using the FastPack PRO System, a point-of-care diagnostic tool. CEO Michael Poirier emphasized the importance of this testing for tracking COVID-19 and aiding in vaccine deployment. Qualigen has over 20 years of experience in diagnostics and has generated over $100 million in sales from its FastPack System.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.63%
Tags
covid-19
Rhea-AI Summary

Qualigen Therapeutics, Inc. (NASDAQ: QLGN) announced a definitive agreement for an $8 million registered direct offering. The agreement includes the sale of 1,200,000 common shares, 780,198 pre-funded warrants, and 1,980,198 common warrants at a price of $4.165 per unit, with the common warrants priced at $5.25 per share. The offering, set to close around July 10, 2020, aims to bolster the company’s financial position. A.G.P./Alliance Global Partners is the sole placement agent for this transaction.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.41%
Tags

FAQ

What is the current stock price of Qualigen Therapeutics (QLGN)?

The current stock price of Qualigen Therapeutics (QLGN) is $3.26 as of July 17, 2025.

What is the market cap of Qualigen Therapeutics (QLGN)?

The market cap of Qualigen Therapeutics (QLGN) is approximately 5.8M.
Qualigen Therapeutics Inc

Nasdaq:QLGN

QLGN Rankings

QLGN Stock Data

5.76M
708.69k
3.77%
1.47%
10.22%
Biotechnology
Pharmaceutical Preparations
Link
United States
CALIFORNIA